Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-12-02

Clinical Trial Update: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination immunotherapy with Herceptin and the HER2 vaccine NeuVax in breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HERCEPTIN (trastuzumab)
  • NeuVax (nelipepimut-S)

Snippet

Sponsor: George E. Peoples | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-12-02